Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 22, 2011

Premium

Silence Therapeutics has named COO Thomas Christely as its new CEO.

He replaces Philip Haworth, who left the company as part of the UK-based company's previously announced reorganization into a wholly European RNAi drugs shop. Haworth was based in California.

Christely served as CFO, and later CEO, of Atugen, an RNAi company that was later acquired by Silence. Before that, he was senior vice president and CFO of OXO Chemie, a Swiss pharmaceutical firm.

Silence also announced that it has appointed Tony Sedgwick as its chief business officer.

He was most recently CEO of biotech firm Novacta. Before that, he served as the CEO of Cambridge Biotechnology and Daniolabs.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.